| Literature DB >> 30106578 |
Eric A Wold, Jianping Chen, Kathryn A Cunningham, Jia Zhou.
Abstract
G-protein-coupled receptors (GPCRs) have been tractable drug targets for decades with over one-third of currently marketed drugs targeting GPCRs. Of these, the class A GPCR superfamily is highly represented, and continued drug discovery for this family of receptors may provide novel therapeutics for a vast range of diseases. GPCR allosteric modulation is an innovative targeting approach that broadens the available small molecule toolbox and is proving to be a viable drug discovery strategy, as evidenced by recent FDA approvals and clinical trials. Numerous class A GPCR allosteric modulators have been discovered recently, and emerging trends such as the availability of GPCR crystal structures, diverse functional assays, and structure-based computational approaches are improving optimization and development. This Perspective provides an update on allosterically targeted class A GPCRs and their disease indications and the medicinal chemistry approaches toward novel allosteric modulators and highlights emerging trends and opportunities in the field.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30106578 PMCID: PMC6556150 DOI: 10.1021/acs.jmedchem.8b00875
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446